ReviewFrontiers in endocrinology2026
Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome describes a multidirectional network linking dysfunctional adiposity, metabolic risk factors, kidney disease and cardiovascular injury. Its early stages are often clinically silent, while obesity, impaired kidney function, multimorbidity and recent exercise can alter the concentrations and interpretation of commonly used biomarkers. This narrative review, informed by a structured literature search, evaluates biomarkers across screening, risk stratification, treatment monitoring and precision phenotyping, while distinguishing CKM-specific evidence from evidence extrapolated from chronic kidney disease, diabetes, obesity and heart-failure populations. Established clinical biomarkers, including estimated glomerular filtration rate, urine albumin-to-creatinine ratio, B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin, remain the foundation of clinical assessment. Emerging evidence spans directly measured markers of inflammation, oxidative stress and organ injury; indices derived from routine clinical variables; and metabolomic, lipidomic and other multi-omics platforms. Most of these measures provide biological or prognostic information but remain investigational because prospective external validation, analytical standardisation, actionable thresholds, incremental net benefit and biomarker-guided intervention evidence are limited. Lifestyle and exercise act both as upstream modifiers of CKM biology and as interpretive factors for several biomarkers. A clinically useful CKM biomarker framework should therefore integrate evidence maturity, population relevance, cross-organ specificity, serial trajectories, cost and equity. Emerging biomarkers should complement rather than replace established assessment until prospective studies demonstrate that their use changes treatment decisions and improves patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.